middle.news
Vectus gets a clearer FDA path for VB0004 lung fibrosis trial
8:37am on Monday 16th of November, 2026 AEDT
•
Biotechnology
Read Story
Vectus gets a clearer FDA path for VB0004 lung fibrosis trial
8:37am on Monday 16th of November, 2026 AEDT
Key Points
Supportive FDA responses on VB0004’s CMC, nonclinical and clinical packages
Guidance covers the planned Phase Ib/IIa IPF study
IND package being finalised with Cardinal Health Regulatory Sciences
Study is planned to commence in Australia
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE